Business
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of
About this update from Canton Strategic Holdings, Inc.
[{"type":"text","content":"BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments to its executive leadership and board of directors, reinforcing its commitment to advancing its pipeline and strategic initiatives. The Company is advancing its lead candidate TH104 specifically designed through a buccal film formulation to deliver an opioid antagonist rapidly and predictably. This allows TH104 to be suitable for the temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders who may be exposed to high-potency opioids, including weaponized fentanyl and its analogues.The Company announced, effective in June 2025, Sireesh Appajosyula assumed the role of Chief Executive Officer. He previously served as Chief Operating Officer, a position he held since July 2023, while concurrently contributing as a member of the board of directors since July 2021. His prior experience includes serving as Senior Vice President, Corporate Development and Operations at a biopharmaceutical company specializing in rare and unmet medical needs. Over the course of the last decade or more, he has co-founded a biotechnology startup and has held various positions of increasing responsibility at Salix Pharmaceuticals until its acquisition by Bausch Health. Earlier, his career encompassed diverse roles at Amgen, Critical Therapeutics, (now Chiesi), and Aventis (now Sanofi). He earned both his Bachelor of Science and Doctor of Pharmacy degrees from Rutgers University.\"I am honored and excited to lead Tharimmune during this pivotal time as we continue to advance our innovative therapeutic candidates,\" said Dr. Sireesh Appajosyula. \"I look forward to working closely with our talented team, dedicated board, and strategic advisors to achieve our mission of delivering impactful treatments for high unmet needs.\"Vincent LoPriore, who has served as a member of Tharimmune's board of directors since April 2025, has been appointed Executive Chairman of the Board.Mr. LoPriore is a highly experienced financial professional with over 30 years in the investment banking industry. He began his distinguished career at Oppenheimer & Co. in 1989, ...